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PEMBANGUNAN DAN PENCIRIAN PEMBAWA LIPID NANOSTRUKTUR 
(NLC) BERMUATAN LOPINAVIR DAN VERAPAMIL HCL 
 
 
ABSTRAK 
 
      Tujuan kajian ini adalah untuk menyediakan pembawa lipid nanostruktur 
(NLC) lopinavir (tidak larutair) dan verapamil (larut air). NLC disediakan dengan 
menggunakan lipid pepejal (compritol 888 ATO), lipid cecair (asid oleik), dan 
surfaktan (poloxamer 188 dan Tween 80). Formulasi NLC disediakan dengan 
menggunakan teknik penyeragaman ricih tinggi. Reka bentuk faktorial 24 penuh 
digunakan dalam mengoptimumkan formulasi. Kesan empat pembolehubah tidak 
bersandar, termasuk masa penyeragaman, kepekatan lipid pepejal, cecair lipid dan 
surfaktan ke atas pembolehubah bersandar iaitu saiz zarah, indeks polisebaran (PDI), 
potensi zeta (ZP) dan kecekapan % pemerangkapan (EE) telah dikaji. Formulasi NLC 
bermuatan drug terpilih di beku-kering menggunakan trehalose sebagai agen 
pelindung. NLC bermuatan lopinavir beku-kering optimum (LOP-3) mempunyai 
purata saiz zarah, PDI, ZP dan % EE masing-masing 286.8 ± 1.3 nm, 0.413 ± 0.017, -
48.6 ± 0.888 mV dan 87.83 ± 2.04%. NLCS bermuatan verapamil beku-kering 
optimum (VER-9) mempunyai saiz zarah, PDI, ZP dan% EE masing-masing 192.29 ± 
2.98 nm, 0.553 ± 0.075, -48.8 ± 0.569 dan 93.26 ± 2.66%. Kajian pelepasan in vitro 
formulasi optimum LOP-3 dan VER-9 dalam bendalir simulasi gastrik (pH 1.2) dan 
bendalir simulasi usus (pH 6.8) masing-masing menunjukkan pelepasan pantas dan 
pelepasan bertahan. Kajian diferensial imbasan kalorimetri kedua-dua formulasi 
(LOP-3 dan VER-9) menunjukkan tiada interaksi kimia antara drug, lipid dan eksipien 
lain. Kajian sudut lebar X-ray penyerakan mengesahkan keadaan amorfus drug yang 
dimuatkan dalam kedua-dua formulasi LOP-3 dan VER-9. Imej TEM kedua-dua 
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formulasi LOP-3 dan VER-9 menunjukkan nanopartikel berbentuk bukan sfera dengan 
masing-masing saiz <100 dan <200 nm. Imej SEM menunjukkan bahawa trehalose 
mengurangkan agregasi formulasi LOP-3 dan VER-9. Kajian in vitro pengambilan 
selular formulasi LOP-3, VER-9 dan ampaian drug bebas yang dilakukan 
menggunakan Caco-2 garis sel, menunjukkan pengambilan drug yang lebih tinggi 
daripada formulasi NLC berbanding ampaian drug bebas. Profil farmakokinetik 
formulasi LOP-3 berikutan pemberian intraduodenal kepada tikus jantan Wistar 
menunjukkan bahawa bioavailabiliti relatif LOP-3 telah meningkat sebanyak 12.25 
kali ganda berbanding ampaian lopinavir bebas. Kajian kestabilan jangka pendek 
formulasi LOP-3 dan VER-9 dilakukan pada empat masa (0, 1, 3 dan 6 bulan) dan 
pada tiga keadaan penyimpanan yang berbeza (5 ° C ± 3 ° C, 25 ° C ± 2 ° C / 60% RH 
± 5% RH dan 40 ° C ± 2 ° C / 75% RH ± 5% RH). Formulasi LOP-3 dan VER-9 stabil 
pada penyimpanan sejuk (5 ° C ± 3 ° C). Jangka hayat formulasi LOP-3 dan VER-9 
masing-masing adalah 18.84 dan 30.55 bulan. Kesimpulan, NLC bermuatan lopinavir 
dan verapamil HCl telah berjaya dibangunkan untuk penghantaran oral dan boleh 
sebagai alternatif kepada produk yang ada dipasaran untuk meningkatkan 
bioavailability oral. 
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DEVELOPMENT AND CHARACTERIZATION OF LOPINAVIR AND 
VERAPAMIL HCL-LOADED NANOSTRUCTURED LIPID CARRIERS 
(NLC)  
 
 
ABSTRACT 
 
      The aim of the present study was to prepare nanostructured lipid carriers 
(NLCs) of lopinavir (water insoluble) and verapamil (water soluble). NLCs were 
prepared using solid lipid (e.g. compritol 888 ATO), liquid lipid (e.g. oleic acid), and 
surfactants (e.g. poloxamer 188 and tween 80). The NLCs formulation was prepared 
using a high shear homogenization technique. The 24 full factorial design was applied 
in the optimization of formulations. The effect of four independent variables, including 
homogenization time, solid lipid, liquid lipid and surfactant concentrations on the 
dependent variables, namely particle size, poly dispersity index (PDI), zeta potential 
(ZP) and % entrapment efficiency (EE) were studied. The selected drug loaded NLCs 
formulations were freeze-dried using trehalose as a cryoprotectant. The optimized 
freeze-dried lopinavir loaded NLCs (LOP-3) had mean particle size, PdI, ZP and % 
EE of 286.8±1.3 nm, 0.413±0.017, -48.6±0.888 mV and 87.83 ± 2.04 %, respectively.  
The optimized freeze-dried verapamil loaded NLCs (VER-9) had mean particle size, 
PdI, ZP and % EE of 192.29 ± 2.98 nm, 0.553 ± 0.075, -48.8±0.569 and 93.26 ± 2.66 
% respectively. In vitro release studies of optimized LOP-3 and VER-9 formulations 
in simulated gastric fluid (pH 1.2) and simulated intestinal fluid (pH 6.8) showed a 
burst and sustained release, respectively. The Differential scanning calorimetry study 
of both formulations (LOP-3 and VER-9) revealed the absence of chemical interaction 
between the drug, lipids and other formulation excipients. The wide angle X-ray 
scattering study revealed the amorphous state of loaded drug in both LOP-3 and VER-
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9 formulations. TEM image of both LOP-3 and VER-9 formulations showed non-
spherical shape nanoparticles with size of <100 and <200 nm respectively. SEM 
images showed that trehalose reduced aggregation of LOP-3 and VER-9 formulations. 
The In vitro cellular uptake studies of LOP-3, VER-9 formulations and free drug 
suspensions performed using Caco-2 cell line showed higher drug uptake from the 
NLCs formulations than the free drug suspension. The pharmacokinetic profile of 
LOP-3 formulation following intraduodenal administration of the formulation to male 
Wistar rats showed that the relative bioavailability of LOP-3 was increased by 12.25-
fold compared to the free lopinavir suspension. The short term stability studies were 
performed for LOP-3 and VER-9 formulations at four time points (0, 1, 3 and 6 
months) and three different storage conditions (5°C ± 3°C, 25°C ± 2°C/60% RH ± 5% 
RH and 40°C ± 2°C/75% RH ± 5% RH). The LOP-3 and VER-9 formulations were 
found stable in refrigerated storage condition (5°C ± 3°C). The shelf life of LOP-3 and 
VER-9 formulations were 18.84 and 30.55 months respectively. In conclusion, 
lopinavir and verapamil HCl loaded NLCs were successfully developed for oral 
delivery and could be an alternative to the available marketed products to improve the 
oral bioavailability. 
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1.1 Colloidal drug carriers 
The new technologies employed in drug discovery lead to find many new powerful 
substances. The development of new drugs alone is not sufficient to ensure progress 
in drug therapy. The main and common problems of new drug molecules are poor 
water solubility and inadequate bioavailability. The size reduction is the method of 
choice to enhance the solubility and hereafter the bioavailability of poorly water-
soluble drugs. However, this method only suitable for class II and IV drugs of 
biopharmaceutical classification system (BCS). Therefore, to develop a drug carrier 
system has become an increasing demand to overcome these obstacles. 
 
The ideal properties of the developed carrier system should have higher drug loading 
capacity, controlled release, possibility of drug targeting and free of acute and chronic 
toxicity. It should also offer chemical and physical stability for the loaded drug. The 
feasibility of production scaling up with reasonable overall costs should be available 
(Barratt, 2000; Mehnert & Mäder, 2001; Mainardes & Silva, 2004; Roger et al., 2010).  
  
The colloidal carriers system, particularly those in the nanosize range, have been 
increasingly investigated in the last several years because they can fulfill the required 
properties mentioned above (van de Waterbeemd, 1998; Dressman & Reppas, 2000). 
 
CHAPTER 1
INTRODUCTION AND LITRATURE REVIEW 
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 1.1.1 Microemulsions and nanoemulsions 
Microemulsions are optically isotropic, transparent or translucent, low-viscous, single-
phase liquid solutions. They are thermodynamically stable bicontinuous systems, 
which are essentially composed of water, oil, surfactant and co-surfactant (Cortesi & 
Nastruzzi, 1999; Heuschkel et al., 2008; Santos et al., 2008; Flores et al., 2016).  
Microemulsions exhibit better solubilizing capacities for both hydrophilic and 
lipophilic drugs than micellar solutions. Due to the high surfactant concentration in 
microemulsions, they are usually limited to dermal and peroral applications.  
 
In the 1950's, nanoemulsions were introduced for the purposes of parenteral nutrition. 
They are heterogeneous systems composed of two immiscible liquids in which one 
one liquid is dispersed as droplets in the other one and the obtained liquid-liquid 
dispersion shows thermodynamic instability ( Yukuyama et al., 2016; Ganta et al., 
2014). Nanoemulsions have been used since some decades as drug carriers for 
lipophilic actives. Several pharmaceutical products based on nanoemulsion system 
have been introduced to the market e.g. Diazepam Lipuro®, Etomidat Lipuro®, 
Stesolid®, Valium®, Diazemuls® and NANOSTAT™ (Chime et al., 2014). 
 
The advantages of nanoemulsions over microemulsions in terms of drug delivery are 
the reduction of the local and systemic side effects, for example lesser pain during 
injection and hemolytic activity caused by the high emulsifying agent concentration in 
microemulsions (Yukuyama et al., 2016). However, the lipophilic loaded drug can 
move from the oil droplets to the aqueous medium due to their partition effects and 
hence, stability problems arise (Dingler et al., 2008). Furthermore, the possibility of 
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 controlled drug release from nanoemulsions is limited due to the high mobility of the 
loaded drug which is dissolved in the oily phase. Ammar et al., (2009) highlighted a 
rapid release of the drugs from nanoemulsions. 
 
1.1.2 Nanocapsules and polymeric nanoparticles 
Nanocapsules consist of a barrier made from polymers between the core (usually oil) 
and the aqueous surrounding environment. Interfacial polymerization and solvent 
displacement methods are often used for nanocapsules preparation ( Letchford & Burt, 
2007; Kothamasu et al., 2012). Polymers used in the formulation of nanocapsules 
include cellulose derivatives, poly methylidene malonate, poly alkylcyanoacrylates, 
polyanhydrides, polyorthoesters and polyesters for example poly glycolic acid, poly 
lactid acid and poly ε-caprolactone and their copolymers (Mora-Huertas et al., 2010). 
Various procedures are applied for polymeric nanoparticles production e.g. solvent 
evaporation, coacervation technique, interfacial polymerization, degradation by high-
shear forces (high pressure homogenization or micro fluidization) and natural proteins 
or carbohydrates denaturation or desolvation (Mora-Huertas et al., 2010; Kothamasu 
et al., 2012). 
 
In comparison to liposomes and emulsions, the presence of polymeric barrier in 
nanocapsules and solid polymeric matrix in polymeric nanoparticles can provide more 
protection to the loaded drug molecules (Mayer, 2005; Anton et al., 2008; Mora-
Huertas et al., 2010). Currently, these carriers have come in the market in the name of 
some pharmaceutical products e.g. Enantone Depot®, Decapeptyl® and Gonapeptyl 
Depot®. 
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 1.2 Lipid-based nanoparticles  
1.2.1 Liposomes  
Liposomes consist of single or multi lipid bilayers of amphiphilic lipids, such as 
phospholipids, glycolipids and cholesterol (Allen & Cullis, 2013). Liposomes were 
described in 1965 by Bangham et al. as a cell membrane model (Bangham, 1992). 
Later on they were used as a carrier system and were introduced to the cosmetic market 
by Dior in 1986. The first topical liposomal pharmaceutical product in the brand name 
of Pevaryl®-Lipogel was produced by Cilag. Comprehensive biodisposition studies 
showed the superiority of the liposomes over the commercial Pevaryl gel, lotion and 
cream forms. The liposomal products resulted in an increase in drug concentration in 
the epidermis (7-9 folds), at the site of action (Touitou et al., 1994). The liposomal 
products displayed less toxicity in contrast to the conventional formulations of the 
same active pharmaceutical ingredients (Fassas & Anagnostopoulos, 2005; 
Akbarzadeh et al., 2013). The liposomes size ranges in between few nanometers to 
some micrometers. There are many methods to prepare the liposomes, e.g. solvent 
dispersion, detergent dialysis and mechanical dispersion ( Elsayed et al., 2007; Samad 
et al., 2007; Akbarzadeh et al., 2013).  The hydrophilic and lipophilic drugs can be 
encapsulated into the liposomes and due to liposomal composition, this carrier system 
are also acceptable for intravenous dosage form (Müller et al., 2000; Allen & Cullis, 
2013;). During storage, it shows some physical and chemical instability due to 
unsaturated fatty acid oxidation and phospholipids ester binding hydrolysis. Moreover, 
due to lack of proper production methods, it cannot produce on large scale easily. All 
of these points make liposomes not optimal as a pharmaceutical carrier system. To 
overcome some of the liposomes drawbacks, niosomes were developed. The niosomes 
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 was prepared by saturated hydrocarbon chains with intramolecular ether bindings that 
increases its chemical stability (Choi & Maibach, 2005; Allen & Cullis, 2013). 
 
1.2.2 Solid lipid nanoparticles (SLNs) 
SLNs are prepared by substituting the oil (liquid lipid) of oil in water emulsion by a 
solid lipid or a blend of solid lipids. This mixture produced solid nanoparticles which 
stay solid at both body and room temperature (Lucks Stefan, 1993; Parhi & Suresh, 
2012). SLNs are comprised of 0.1%w/w to 30%w/w of solid lipid with respect to the 
amount of whole formulation and usually it stabilized with 0.5%w/w to 5%w/w of 
surfactant with respect to lipid content. The size of SLNs ranged in submicron region, 
i.e. extending from around 40 nm to 1 micron (Lucks Stefan, 1993; Parhi & Suresh, 
2012). 
 
Moreover, after the preparation at least a part of the solid lipid in SLNs crystallizes in 
a higher energy modification (α or β`). During storage, these modifications can 
transform to the low energy, more ordered β modification. Due to this high degree of 
order, the number of imperfections in the SLNs crystal lattice is small, this leads to 
drug expulsion (Mehnert & Mäder, 2001; Müller et al., 2002b).  
 
1.2.3 Nanostructured lipid carriers (NLCs) 
NLCs have been developed to overcome the drawbacks associated with SLNs. They 
are considered to be the second generation of lipid nanoparticles. Compared to SLNs, 
NLCs show a higher loading capacity for active compounds by creating a less ordered 
solid lipid matrix, i.e. by blending a liquid lipid with the solid lipid, a higher particle 
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 drug loading can be achieved. Therefore, the NLCs have an increased drug loading 
capacity in comparison to SLNs and the possibility of drug expulsion during storage 
is less (Müller et al., 2002a; Müller et al., 2002b; Saupe et al., 2005; Naseri et al., 2015; 
Khan S et al., 2015). NLCs have also a lower water content of the particle suspension 
and a less tendency of unpredictable gelation (Müller et al., 2002a; Naseri et al., 2015). 
 
1.2.3(a) NLCs composition  
NLCs are prepared using combinations of solid and liquid lipids (oils). Herein solid 
lipids and liquid lipids are mixed together at ratio of 70:30 to 99.9:0.1 to obtain the 
controlled structured particle matrix. The obtained blends are solid at body and room 
temperature rather than present as oil (liquid lipids) in the mixture (Müller et al., 2000). 
The total solid content of NLCs can be enhanced up to 95% (Selvamuthukumar & 
Velmurugan, 2012) 
 
1.2.3(b) Methods of NLCs preparation  
Various methods have been used for the preparation of NLCs. The methods are 
microemulsion technique (Gupta et al., 2014), emulsification-solvent evaporation 
(Andalib et al., 2012), multiple emulsion technique (Selvamuthukumar & 
Velmurugan, 2012), solvent injection (or solvent displacement) (Tiwari & Pathak, 
2011), ultrasonication (Uprit et al., 2013), phase inversion (Ming Sun et al., 2014) 
(Ming Sun et al., 2014), membrane contractor technique (Thatipamula et al., 2011), 
high-pressure homogenization (Shangguan et al., 2014) and high-shear 
homogenization (Ustündağ-Okur et al., 2014). High shear-homogenization is very 
common technique for lipid based nanoformulations. It shows several benefits over 
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 other techniques for example, easy production scale-up, lesser process time and 
avoidance of organic solvent. For these reasons, it is widely accepted in several 
productions areas such as pharmaceutical and food industry.  
 
1.2.3(c) Characterization of NLCs  
Characterization of NLCs may be a serious challenge because of the small size of the 
particles resulting in the complexity of the system. Therefore, characterization of the 
NLCs may be an essential requisite for the management of the quality of the product. 
Many parameters need to be considered that have direct impact on the stability and 
release kinetics of NLCs such as particle size, polydispersity index and zeta potential. 
 
1.2.3(d) Stability of NLCs  
Among the hurdles in lipid based nanoparticles development, the long-term instability 
of lipid based nanoparticles dispersions is undoubtedly a major concern. In order to 
prolong the physical and chemical stability of the NLCs the water removal is a 
necessary step.  The best common method in the pharmaceutical field is freeze drying 
which allows to change aqueous formulation into dried formulation for sufficient 
stability during storage (Franks, 1998; Varshosazet et al., 2012). Pharmaceutically, it 
is also known as lyophilization. It removes water from the frozen sample via 
sublimation and then desorption of that vapors take place under vacuum. 
 
1.2.3(e) Role of NLCs in different delivery system  
NLCs are used as biocompatible carriers for several types of drugs intended for 
pharmaceutical, cosmetic, and biochemical purposes. During the last one decade 
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 different drugs or active substances have been entrapped into NLCs like lipophilic, 
hydrophilic molecules, including labile compounds, such as proteins and peptides. 
Their main feature is that they are prepared with physiologically well-tolerated lipids. 
The wide range of surfactants and cosurfactants available for the production of such 
particles make these carriers highly suitable for distinct applications like for topical, 
oral, parenteral, inhalational and ocular administration.  
 
1.2.3(f) NLCs versus SLNs  
As mentioned previously NLCs overcome the disadvantages associated with SLNs, in 
other words, they provide higher drug loading, faster release rate and storage stability 
due to a use of blend of solid lipid and liquid lipid in their formulations. Several 
comparative studies have been documented in literature in which NLCs have served 
as a better carrier than SLNs. For example, in a study between SLNs and NLCs of 
simvastatin, it was observed that entrapment efficiency of the drug was improved in 
NLCs (93.33%) when compared with SLNs (75.81%) due to creation of extra space 
for loading by liquid lipid (Tiwari & Pathak, 2011). Also, the in vitro release patterns 
in both SLNs and NLCs were similar but NLCs displayed high-percent cumulative 
drug release in comparison to SLNs in 55 h. A lesser mobility of drug in SLNs (a 
crystallized system) in comparison to NLCs (disordered arrangement) was responsible 
for the slower release of drug. Differential scanning calorimetric analysis showed 
decreased recrystallization index of NLCs in comparison to solid lipids and physical 
mixture of solid lipid and liquid lipid favoring the formation of disordered arrangement 
and reduced capacity of solid lipids to recrystallize suggesting their higher long-term 
stability. The results of in vivo studies also suggested NLCs to be superior as they 
exhibited 2.29-fold increase in oral bioavailability when administered to mice. Similar 
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 results were also noted with lovastatin-loaded NLCs. Study of partitioning behavior 
of lovastatin in pure solid lipid and mixtures of solid lipid and liquid lipid also depicted 
higher partitioning of drug in the lipid phase consisting of a mixture of solid lipid 
(Precirol ATO 5) and liquid lipid (squalene) thus suggesting that higher solubility of 
drug was favored by the presence of liquid lipid (Chen et al., 2010). Another report on 
progesterone (Yuan, Wang, et al., 2007) and domperidone-loaded (Thatipamula et al., 
2011) SLNs and NLCs also suggested the NLCs as a better vehicle in respect of drug 
loading and release rate (Poonia, Kharb, Lather, & Pandita, 2016).  
 
1.3 Lipid based nanoparticles as a carrier for oral drug delivery  
Lipid based nanoparticles for example SLNs and NLCs can be given by oral route in 
tablet, capsules, pellets, dispersions and as lyophilized powders ready for 
reconstitution (Mehnert & Mäder, 2001). The GIT stability of lipid nanoparticles has 
to be comprehensively studied, the acidic pH and elevated ionic strength in the upper 
GIT could result in lipid nanoparticles aggregation. So, to verify this, some authors 
investigated different lipid nanoparticle formulations behavior in simulated gastric 
fluids. They observed that zeta potential of a minimum 8-9 mV might hinder lipid 
nanoparticles aggregation (Zimmermann & Müller, 2001). Furthermore, to optimize 
the release profile of lipid nanoparticles, the knowledge of enzymatic degradation of 
lipids during in vivo drug release studies is essential (Olbrich & Müller, 1999). Since, 
in vivo release media contain lipolytic enzyme (pancreatic lipase) and drug release take 
place by lipid matrix degradation and solid phase diffusion process. While, in vitro 
drug release take place by solid phase diffusion, due to absence of lipolytic enzyme. 
Olbrich & Müller (1999), established an enzymatic degradation assay of SLNs using 
a lipase/colipase complex. In that, it shown that the degradation velocity depends on 
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 the composition of the lipid matrix. In general, degradation velocity increased with 
decreasing length of the fatty acid chain length when using glycerides as lipid matrix. 
In addition, the degradation of SLNs based on waxes (e.g. cetylpalmitate) was found 
to be slower compared to glyceride matrices (Olbrich & Müller, 1999). A prerequisite 
for the degradation of lipid nanoparticles after oral administration is the anchoring of 
the lipase/ colipase complex onto the particle surface. Therefore, it was expected that 
not only the composition of the lipid matrix, but also the nature of the stabilizing 
surfactant layer would be a determining factor for degradation (Olbrich & Müller, 
1999). Compounds such as cholic acid sodium salt are known to promote the 
anchoring of the lipase colipase complex on surfaces (Borgström, 1975). Sterically 
stabilizing polymers such as the Poloxamer series are known to prevent or to hinder 
the absorption of large molecules such as proteins (Blunk et al., 1993).  
 
1.4 The drug absorption of lipid-based nanoparticles via lymphatic circulation 
The lymphatic system is part of the circulatory system and is comprised of an intricate 
network of conduits that carry a clear fluid called lymph. The primary functions of the 
lymphatic system are to maintain the body’s water balance by returning extracellular 
fluid that has leaked out into the interstitial space back to the systemic circulation and 
to transport immune cells to the lymph nodes (Iqbal & Hussain, 2009; Miteva et al., 
2010). Further, the lymphatic system has specialized roles in specific areas because of 
its nonuniform structure and function throughout the body. It plays an essential role in 
absorption of long- chain fatty acids, triglycerides, cholesterol esters, lipid soluble 
vitamins, and xenobiotics (Iqbal & Hussain, 2009). Drug delivery via the lymphatic 
system has several major advantages, including circumventing first-pass metabolism 
in the liver and targeting drugs to diseases that spread through the lymphatic system 
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 (eg, certain types of cancer and human immunodeficiency virus). The lymphatic 
system also plays an active role in disseminating metastatic cancer cells and infectious 
agents throughout the body. Cancer cells use the lymph nodes as a reservoir to spread 
to other areas of the body (Sleeman, 2000, 2006; Pantel & Brakenhoff, 2004; Lee et 
al., 2005; Iqbal & Hussain, 2009). 
 
There are three ways to deliver drugs through the intestinal lymphatic vessels 
(Muranishi et al., 1997; Porter & Charman, 1997). First, lymphatic capillaries are 
comprised of single-layered, nonfenestrated endothelial cells. These cells are arranged 
in a highly gapped and overlapped manner to form a porous wall in the lymphatic 
vasculature, which allows for macromolecular targeting to the lymphatic system. 
Therefore, increased absorption of hydrophilic macromolecules and macroconjugates 
is possible by opening up the paracellular route with the help of an absorption enhancer 
(Hiroshi et al., 1981). Secondly, gut-associated lymphoid tissue consists of either 
isolated or aggregated lymphoid follicles that form Peyer’s patches, which provide an 
entry point for drug to the lymphatics (Figure 1.1 A) (Eldridge et al., 1990; Hawley, 
Davis, & Illum, 1995; Beier & Gebert, 1998; Wells & Mercenier, 2008). Finally, the 
primary route for lipid transport is through the intestinal walls via transcellular 
absorption, paracellular transport, P-glycoprotein, and cytochrome P450 inhibition. 
Increased production of chylomicrons is associated with delivery of lipophilic 
compounds into the lymphatic system (Figure 1.1 B) ((Porter & Charman, 1997). 
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Figure 1.1 A Schematic transverse section of Peyer’s patch, illustrating M cell 
transportation of lipid based formulation (nanostructured lipid carriers) to the 
lymphatic vessels. B Schematic diagram of the different mechanisms of the intestinal 
transport of lipid based formulation (nanostructured lipid carriers) through blood and 
lymphatic circulation. Adopted from Khan et al., (2013). 
Abbreviations: P-gp, P-glycoprotein; CYP450, cytochrome P450 enzyme; M cell, 
membranous cell.  
 
A number of lipid-based formulations, including emulsions, micellar systems, self-
emulsifying drug delivery systems, self-microemulsifying drug delivery systems, self-
nanoemulsifying drug delivery systems, liposomes, solid lipid nanoparticles (SLNs), 
and nanostructured lipid carriers (NLCs) have been investigated as drug carriers for 
the lymphatic system (table 1.1). 
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SLNs offer a prominent advantage over other  nanoparticulate 
systems because they use physiological lipids and  surfactants, 
which are generally recognized as safe. The commonly 
used lipids in the SLNs preparation are fatty acids, waxes, 
 monoglycerides, diglycerides, and triglycerides;  surfactants 
such as poloxamer and polysorbate are also widely 
used.  Further, the possibility of avoiding a solvent using 
high- pressure homogenization can help avoid the carrier 
 biotoxicity problem in humans.64,65 SLNs involve formation 
of a relatively rigid core consisting of lipids that are solid at 
room temperature. Thus, SLNs can help improve stability and 
provide controlled release and drug targeting.66 The minute 
size of this formulation enables efﬁcient uptake of drugs into 
the intestine, particularly via the lymphatic route, involving 
particles only 20–500 nm in diameter.67
Absorption via the lymphatic route can be used for 
delivery of cytotoxic agents to overcome the limitations of 
nonspeciﬁcity, drug resistance, and severe toxicity.68 Several 
cytotoxic drugs have been incorporated into SLNs,  including 
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 Table 1.1 Formulations that have been used for lymphatic delivery 
Formulations Drugs References 
Emulsion  Penclomedine (Myers & Stella, 1992) 
Emulsion Ontazolast (Hauss et al., 1998) 
Microemulsion  Puerarin (Wu et al., 2011) 
Microemulsion Raloxifene (Thakkar et al.,  2011) 
Micellar 
systems 
Cyclosporine A (Takada et al., 1986) 
SEEDS  Coenzyme Q 10 (Kommuru et al., 2001) 
SMEDDS Halofantrine (Holm et al., 2003) 
SMEDDS Nobiletin (Yao et al., 2008) 
SMEDDS Valsartan (Dixit et al., 2010) 
SMEDDS Vinpocetine (Y. Chen et al., 2008) 
SMEDDS Silymarin (Li et al., 2010) 
SMEDDS Sirolimus (Minghui Sun et al., 2011) 
SNEDDS  Carvedilol (Singh et al., 2011) 
SNEDDS Valsartan (Beg et al., 2012) 
SNEDDS Halofantrine (Holm et al., 2012) 
Liposomes  IgG1 (Moghimi & Moghimi, 2008) 
Liposomes Doxorubicin (Frenkel et al., 2006) 
Liposomes Cefotaxime (Ling et al., 2006) 
Liposomes 9-nitro-
camptothecin 
(Lawson et al., 2004) 
Liposomes Paclitaxel (Latimer et al., 2009) 
Liposomes Ovalbumin (Kojima et al., 2008) 
SLNs Etoposide (Harivardhan et al., 2005) 
SLNs Methotrexate (Paliwal et al., 2009) 
SLNs Idarubicin (Zara et al., 2002a) 
SLNs Tobramycin (Cavalli et al., 2000; Cavalli et al., 2003) 
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SLNs Nimodipine (Chalikwar et al., 2012)  
NLCs Testosterone (Muchow et al., 2011) 
NLCs Vinpocetine (Zhuang et al., 2010) 
NLCs Tripterine (Zhou et al., 2012) 
 
Abbreviations: SEEDS, Self emulsifying drug delivery system; SMEDDS, Self-
microemulsifying drug delivery systems; SNEDDS, Self-nanoemulsifying drug 
delivery systems; SLNs, Solid lipid nanoparticles; NLCs, Nanostructured lipid 
carriers. 
 
1.5 Different routes for NLCs lymphatic uptake 
Lipid based nanoformulations such as SLNs and NLCs offer a prominent advantage 
over other nanoparticulate systems because they use physiological lipids and 
surfactants, which are generally recognized as safe. The commonly used lipids in the 
lipid based nanoformulations preparation are fatty acids, waxes, monoglycerides, 
diglycerides, and triglycerides; surfactants such as poloxamer and polysorbate are also 
widely used. Further, the possibility of avoiding a solvent using high-pressure 
homogenization can help to prevent the carrier biotoxicity problem in humans (Müller 
et al., 2000; Wissing et al., 2004). Lipid based nanoformulations involve formation of 
a relatively rigid core consisting of lipids that are solid at room temperature. Thus, 
lipid based nanoformulations can help improve stability and provide controlled release 
and drug targeting (Mehnert & Mäder, 2001). The minute size of these formulations 
enables efficient uptake of drugs into the intestine, particularly via the lymphatic route, 
involving particles only 20–500 nm in diameter (Yuan, Wang, et al., 2007). Absorption 
via the lymphatic route can be used for delivery of cytotoxic agents to overcome the 
limitations of nonspecificity, drug resistance, and severe toxicity (Wong et al., 2007). 
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 There are mainly three different routes have been explored for lymphatic uptake of 
NLCs, including the subcutaneous, pulmonary, and duodenal routes. 
 
1.5.1 Subcutaneous route for lymphatic delivery of NLCs  
The subcutaneous route is an attractive one for lymphatic delivery of NLCs, with 
several advantages, including drug accumulation at the site of administration for a 
longer period of time, low clearance, sustained release, and increased absorption. On 
subcutaneous administration, NLCs are not directly transported into the bloodstream 
because capillaries control the permeability of water and small molecules. Instead, the 
lymphatic capillaries surrounding the subcutaneous injection site absorb the lipid-
based nanoparticles. Absorption of NLCs into the lymphatic system depends primarily 
on the size of the nanoparticles. Larger NLCs accumulate at the injection site, and the 
drug is slowly released from the NLCs. The free drug can enter the blood circulation 
via pores on the walls of the capillaries. Smaller NLCs (not more than 100 nm) can 
easily access the lymphatic capillaries and concentrate in regional lymph nodes 
(Oussoren, 2001). Thus, based on these advantages, NLCs could be developed as a 
carrier for lymphatic drug delivery by subcutaneous administration because they have 
improved physicochemical properties compared with other lipid-based nanocarrier 
systems. 
 
1.5.2 Pulmonary route for lymphatic delivery of NLCs  
Drug administration via the pulmonary route has several advantages compared with 
the oral and parenteral routes. The pulmonary route avoids first-pass metabolism, 
reduces systemic toxicity, noninvasive, minimizes the need for continuous dosing, 
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 allows the drugs administered to reach less accessible parts of the lung directly, and 
enables increased local concentrations of drug (Walker et al., 2009). The pulmonary 
route shows great potential for the delivery of NLCs into the lymphatic circulation. 
The particle size of NLCs can be reduced to less than 500 nm, which could increase 
drug deposition in the lung epithelium because of their diffusional mobility (Jaques & 
Kim, 2000). NLCs are lipid-based nanoparticles that could be used as a carrier for 
targeting drugs to small cell lung cancer and human immunodeficiency virus, both of 
which spread through the lymphatic system and can cross into the systemic circulation 
(Chambers et al., 2002; Pantel & Brakenhoff, 2004). Thus, NLCs have the potential to 
provide a drug delivery mechanism via the lymphatic system through the pulmonary 
route and may have increased effectiveness compared to SLNs. 
 
1.5.3 Intestinal route for lymphatic delivery of NLCs 
NLCs have the potential to be an effective method for oral drug delivery, because they 
can increase solubility and enhance the oral bioavailability of drugs that are either 
hydrophobic or poorly soluble in water (O’Driscoll & Griffin, 2008). Among the 
traditional lipid-based formulations, NLCs have become an important alternative to 
the more traditional colloidal drug carriers (Müller et al., 2002a). Zhuang et al 
developed drug-loaded NLCs to improve the oral bioavailability of vinpocetine 
(Zhuang et al., 2010). Both vinpocetine-loaded NLCs and a vinpocetine suspension 
were orally administered to male Wistar rats. The time taken to reach maximum 
plasma concentrations (tmax) and the peak concentration reached (Cmax) for the 
vinpocetine suspension were 30 minutes and 354.29 ± 57.49 ng/mL, respectively, 
whereas the tmax and Cmax of vinpocetine-loaded NLCs were 1.5 hours and 679.29 ± 
135.57 ng/mL, respectively. The Tmax for vinpocetine-loaded NLCs was one hour 
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 longer than the vinpocetine suspension, indicating indirect transport of NLCs into the 
systemic circulation. The Cmax for vinpocetine- loaded NLCs was also significantly 
higher than the vinpocetine suspension. The area under the curve for the vinpocetine-
loaded NLCs was 3.2-fold greater than that of the vinpocetine suspension. In vivo 
pharmacokinetic analysis showed a 322% increase in the relative bioavailability of 
vinpocetine-loaded NLCs compared to the vinpocetine suspension after oral 
administration. These results suggest that NLCs can improve the oral bioavailability 
of drug which are poorly soluble in water (Zhuang et al., 2010). One possible reason 
for the enhanced bioavailability of vinpocetine could be that NLCs are transported in 
the lymphatic system, so largely avoid first-pass metabolism, which is the main cause 
for the low bioavailability of vinpocetine (Zhuang et al., 2010).  
 
In another study, Zhou et al., (2012) developed tripterine NLCs and evaluated their 
potential as an oral drug delivery system. A rat intestinal perfusion model was used to 
compare the absorption of tripterine-loaded NLCs with that of a tripterine solution. 
The effective permeability of tripterine NLCs in the duodenum, jejunum, ileum, and 
colon was 2.1, 2.7, 1.1, and 1.2 times higher, respectively, compared with the tripterine 
solution. The percentage absorption of tripterine- loaded NLCs in 10 cm of duodenum, 
jejunum, ileum, and colon was 2.2, 2.3, 1.2, and 1.3 times greater, respectively, than 
for the tripterine solution (Zhou et al., 2012). These results indicate that NLCs could 
be used as a carrier to improve the absorption of tripterine in the gastrointestinal tract.  
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 1.6 In vitro models for studying lymphatic drug transport 
Various in vitro models can serve as an alternative to in vivo models for studying 
lymphatic drug transport. In the intestinal permeability model, Caco-2 cells are used 
to evaluate intracellular lipoprotein-lipid assembly and to examine the effect of lipids 
and lipidic excipients on incorporation of drug with lipoproteins in lymphatic transport 
(Seeballuck et al., 2003; Seeballuck et al., 2004; Karpf et al., 2006). In one in vitro 
model, Gershkovich & Hoffman, (2005) described a correlation between the degree of 
ex-vivo incorporation of a drug into chylomicrons and the extent of intestinal 
lymphatic drug transport. According to a lipolysis model described by Dahan & 
Hoffman, (2008) in vivo drug absorption could be predicted by evaluating drug release 
from a lipid-based drug delivery system and estimating precipitation of the drug during 
lipolysis. Holm & Hoest, (2004) reported an in silico method that established a 
quantitative relationship between the molecular structure and amount of drug 
transferred from the intestinal to the lymphatic system.  
 
1.6.1 In vitro cellular uptake study via Caco-2 cell monolayer model to evaluate 
the indirect lymphatic uptake of NLCs 
The Caco-2 cell line is a heterogeneous human epithelial colorectal adenocarcinoma 
cells that derived from human colon carcinoma. These cells have the ability to 
differentiate and polarized functionally and morphologically as the intestinal 
enterocytes lining when cultured in specific conditions. These cells resemble as 
enterocytes in various aspects of its properties such as microvilli, tight junction, some 
transporters and enzymes. Due to the uniqueness of these cells and lack of proper in 
vitro lymphatic absorption methods these cells have been chosen and used as an 
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 indirect method for the lymphatic uptake study for oral lipid based nanoformulations 
(Shah et al., 2014). 
 
1.6.2 Characteristics of Caco-2 cells 
1.6.2(a) Tight junction 
The Caco-2 monolayers form the tight junction when cells become confluent. The 
integrity of monolayer can be measured by trans-epithelial electrical resistance 
(TEER) and paracellular markers permeability such as mannitol, inulin and lucifer 
yellow across the Caco-2 monolayer (Mukherjee et al., 2008). For paracellular 
transport the pore radius of Caco-2 tight junction is smaller (∼4.5 Å) than the human 
intestinal enterocytes tight junction pore radius (∼8 – 13 Å) (Fine et al., 1995; Watson 
et al., 2001). 
 
1.6.2(b) Drug transporters  
Several transporter and enzyme are present in Caco-2 monolayers same as found in 
intestine. These are H+/di-tripeptide transporter (PEPT1), monocarboxylic acid 
transporter 1 (MCT1), organic anion-transporting polypeptide 2B1 (OATP-B), organic 
cation/carnitine transporter (OCTN2) and apical Na+-dependent bile acid transporter 
(ASBT), all are expressed on apical membrane. Also, the efflux transporter P-
glycoprotein (MDR1) and multidrug resistance-associated protein 2 (MRP2) are 
present on apical membrane (Figure 1.2). These efflux transporter promotes the 
elimination of solute from intracellular site to the basolateral area, as a result to 
enhance the drug absorption (Sun et al.,  2008). 
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 1.6.2(c) Metabolic enzymes  
The Caco-2 monolayers express several metabolic enzymes, for example cytochrome 
P450 1A (CYP1A), UDP-glucuronosyltransferases (UGTs), glutathione S-
transferases (GSTs) and sulfotransferases (SULTs) (figure 1.2). However, the 
Cytochrome P450 3A4 (CYP3A4) usually absent or weakly present in Caco-2 
monolayers (Sun et al.,  2008). 
 
Figure 1.2 Drug transporters and metabolic enzymes present in Caco-2 cell monolayer 
 
Abbreviations: PEPT1, H+/di-tripeptide transporter; OATP-B, organic anion-
transporting polypeptide 2B1; MCT1, monocarboxylic acid transporter 1; ASBT, 
Na+-dependent bile acid transporter; OCTN2, organic cation/carnitine transporter; 
MDR1, or P-glycoprotein, P-gp, multidrug resistance protein 1; MRP2, multidrug 
resistance-associated protein 2; MRP3, multidrug resistance-associated protein 3; 
MRP4, multidrug resistance-associated protein 4; MRP6, multidrug resistance-
associated protein 5; BCRP, breast cancer resistance protein; OSTD/E, organic solute 
transporters; CYP, cytochrome P450; SULTs, sulfotransferases; UGTs, UDP-
glucuronosyltransferases; GSTs, glutathione S-transferases.  
 
